ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
Status:
Completed
Trial end date:
2018-10-18
Target enrollment:
Participant gender:
Summary
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in
combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related
macular degeneration (NVAMD)